Cenix signs research agreement with Boehringer Ingelheim

Cenix will apply its expertise in combining high throughput applications of RNAi-based gene silencing, with high content phenotypic analyses in what will be a genome-scale screen using cultured human cells.

Multi-parametric microscopy-based assays developed by Cenix using the Cellenger image analysis platform from Munich-based Definiens, will be used to complement proprietary assays developed at Boehringer Ingelheim, in order to generate detailed insights into the cellular functions and loss-of-function phenotypes of analyzed genes.

Christophe Echeverri, CEO of Cenix, said: We have long been looking forward to this opportunity to combine our own capabilities with those of our expert colleagues at Boehringer Ingelheim. We expect that the excellent complementarities between the two teams will deliver a particularly productive and cost-effective driver for these programs.

Cenix BioScience, a contract research organization is specialized in combining advanced applications of RNA interference (RNAi) gene silencing with high content phenotypic analyses which enhances the discovery and pre-clinical development of novel therapeutics.

Boehringer Ingelheim is committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.